It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRON’s FA Score shows that 1 FA rating(s) are green whileYCBD’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRON’s TA Score shows that 2 TA indicator(s) are bullish while YCBD’s TA Score has 7 bullish TA indicator(s).
CRON (@Pharmaceuticals: Other) experienced а 0.00% price change this week, while YCBD (@Pharmaceuticals: Other) price change was -2.33% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.47%. For the same industry, the average monthly price growth was +2.65%, and the average quarterly price growth was -7.14%.
CRON is expected to report earnings on May 08, 2025.
YCBD is expected to report earnings on Aug 10, 2023.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
CRON | YCBD | CRON / YCBD | |
Capitalization | 1.01B | 2.62M | 38,373% |
EBITDA | -71.8M | -3.44M | 2,087% |
Gain YTD | -4.455 | 56.267 | -8% |
P/E Ratio | N/A | 0.00 | - |
Revenue | 87.2M | 23.4M | 373% |
Total Cash | 862M | 1.51M | 57,276% |
Total Debt | 2.55M | 3.37M | 76% |
CRON | YCBD | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 63 | 67 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 91 | 99 | |
PRICE GROWTH RATING 1..100 | 76 | 40 | |
P/E GROWTH RATING 1..100 | 1 | 67 | |
SEASONALITY SCORE 1..100 | 75 | 13 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
YCBD's Valuation (49) in the Other Consumer Services industry is in the same range as CRON (70) in the Pharmaceuticals Other industry. This means that YCBD’s stock grew similarly to CRON’s over the last 12 months.
YCBD's Profit vs Risk Rating (100) in the Other Consumer Services industry is in the same range as CRON (100) in the Pharmaceuticals Other industry. This means that YCBD’s stock grew similarly to CRON’s over the last 12 months.
CRON's SMR Rating (91) in the Pharmaceuticals Other industry is in the same range as YCBD (99) in the Other Consumer Services industry. This means that CRON’s stock grew similarly to YCBD’s over the last 12 months.
YCBD's Price Growth Rating (40) in the Other Consumer Services industry is somewhat better than the same rating for CRON (76) in the Pharmaceuticals Other industry. This means that YCBD’s stock grew somewhat faster than CRON’s over the last 12 months.
CRON's P/E Growth Rating (1) in the Pharmaceuticals Other industry is significantly better than the same rating for YCBD (67) in the Other Consumer Services industry. This means that CRON’s stock grew significantly faster than YCBD’s over the last 12 months.
CRON | YCBD | |
---|---|---|
RSI ODDS (%) | N/A | 3 days ago89% |
Stochastic ODDS (%) | 3 days ago77% | 3 days ago89% |
Momentum ODDS (%) | 3 days ago88% | 3 days ago89% |
MACD ODDS (%) | 3 days ago87% | 3 days ago87% |
TrendWeek ODDS (%) | 3 days ago85% | 3 days ago82% |
TrendMonth ODDS (%) | 3 days ago83% | 3 days ago83% |
Advances ODDS (%) | 29 days ago74% | 29 days ago82% |
Declines ODDS (%) | 5 days ago85% | 5 days ago88% |
BollingerBands ODDS (%) | N/A | 3 days ago88% |
Aroon ODDS (%) | 3 days ago89% | 3 days ago82% |
A.I.dvisor tells us that YCBD and CGC have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that YCBD and CGC's prices will move in lockstep.
Ticker / NAME | Correlation To YCBD | 1D Price Change % | ||
---|---|---|---|---|
YCBD | 100% | +6.55% | ||
CGC - YCBD | 32% Poorly correlated | +3.45% | ||
RGEDF - YCBD | 28% Poorly correlated | N/A | ||
TLRY - YCBD | 24% Poorly correlated | +8.65% | ||
ACB - YCBD | 23% Poorly correlated | +3.24% | ||
CRON - YCBD | 23% Poorly correlated | +2.66% | ||
More |